
Capivasertib on the PBS
Drugline Volume 533
Capivasertib has been added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of locally advanced or metastatic breast cancer. Eligibility requires the condition to be human epidermal growth factor receptor-2 (HER2) negative and…
Read more